A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

NCT02431208 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
DRUG: Daratumumab
DRUG: Lenalidomide
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Hoffmann-La Roche